CARCIK-CD19 is a type of cell therapy used in this clinical trial. It involves using specially modified immune cells called CIK cells, which are taken from a donor. These cells are then engineered to express a chimeric antigen receptor (CAR) that targets CD19, a protein found on the surface of certain cancer cells. The goal of this therapy is to help the immune system recognize and attack cancer cells in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia.

Non-Hodgkin Lymphoma – This is a type of cancer that originates in the lymphatic system, which is part of the body’s immune system. It involves the abnormal growth of lymphocytes, a type of white blood cell, which can form tumors throughout the body. The disease can start in lymph nodes, spleen, or other lymphatic tissues and may spread to other organs. Non-Hodgkin Lymphoma can vary greatly in its progression, with some forms growing slowly and others more aggressively. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss. The exact cause is often unknown, but it involves genetic mutations in the lymphocytes.

Chronic Lymphocytic Leukemia – This is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of abnormal lymphocytes. It typically progresses slowly and is most common in older adults. The disease may not cause symptoms initially, but as it advances, it can lead to fatigue, swollen lymph nodes, and frequent infections. Over time, the abnormal cells can crowd out healthy blood cells, leading to anemia and other complications. The cause of Chronic Lymphocytic Leukemia is not fully understood, but it involves genetic changes in the lymphocytes.